Drostanolone Enanthate
Extended-release DHT-derived compound with 10-day half-life for sustained stable levels.
Drostanolone Enanthate
Drostanolone Enanthate is a sterile oil-based injectable preparation of drostanolone esterified with enanthic acid, presented at 250 milligrams per millilitre in a 10 mL multiple dose vial. It provides the non-aromatising profile of drostanolone with a substantially extended release phase compared with the propionate ester.
Structural Profile
The active moiety is drostanolone, 2-alpha-methyl-dihydrotestosterone. The 2-alpha methyl substitution confers resistance to enzymatic inactivation and raises anabolic potency. Esterified with enanthic acid at the 17-beta hydroxyl, the molecular formula is C27H44O3 with a molar mass of 416.64 g/mol.
Esterification and Release
The seven-carbon enanthate chain is considerably more lipophilic than propionate, prolonging residence in the intramuscular depot. Serum concentrations are correspondingly steadier and the interval between administrations can be extended from days to a week or more.
Pharmacokinetic Profile
The elimination half-life is approximately 10 days. Concentrations rise over the first days after administration and decline gradually thereafter, producing a stable plasma curve. The urinary detection window extends to approximately 3 months, substantially longer than for the propionate ester as a consequence of prolonged depot release.
Mechanism of Action
Drostanolone binds the cytoplasmic androgen receptor; the hormone-receptor complex translocates to the nucleus and engages androgen response elements, upregulating transcription of genes governing structural protein synthesis. Being a dihydrotestosterone derivative, the molecule cannot be aromatised to oestradiol, and it exhibits weak anti-oestrogenic activity through competitive interaction with aromatase.
Manufacturing and Sterility
Each production lot is released against the complete pharmaceutical testing protocol: HPLC identity confirmation and purity analysis with a specification of not less than 98 percent, verification of concentration against label claim within 5 percent, sterility testing in accordance with USP <71>, bacterial endotoxin quantification by LAL assay below 0.25 EU/mL, and particulate matter inspection in accordance with USP <788>. A Certificate of Analysis is issued for every lot.
Quality Assurance
Every batch of Drostanolone Enanthate produced by Biomedica undergoes the complete pharmaceutical release testing protocol before distribution. This includes HPLC compound identity confirmation and purity analysis (specification: ≥98%), concentration verification (specification: ±5% of label claim), sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay (specification: <0.25 EU/mL), and particulate matter inspection per USP <788>. A Certificate of Analysis is issued for every production lot.
Authentication
Each unit of Drostanolone Enanthate carries a unique authentication code on its outer packaging. This code can be verified instantly on our Authentication page to confirm the product is genuine Biomedica stock.